Joël oversees all operations at Ysios Capital, including management, strategy and day-to-day operations.
Previously, in 2001, Joël co-founded Glycart Biotechnology and was its CEO until its sale to F. Hoffmann La-Roche four years later. Glycart Biotechnology was the originator of the anti-CD20 antibody – obinituzumab/Gazyva® – the first breakthrough designated drug approved by the FDA in 2013.
Joël was elected one of the 50 key players in biotechnology in Switzerland in 2003 and earned several innovation awards for Glycart Biotechnology, including the Wall Street Journal Europe Innovation Award in 2001.
Joël holds a MSc in Biotechnology and a PhD in the fields of Cell Biology and Immunotherapeutics, both from the Swiss Federal Institute of Technology (ETH Zürich).
Joël serves on the Boards of Adcendo, Ona Therapeutics,Chairman at Inbiomotion, and Board Observer at AM-Pharma and Mineralys Therapeutics. Formerly, he was Board Observer at Biovex (acquired by Amgen), Chairman of the Board at Cellerix/TiGenix (acquired by Takeda), and Board Member at Splice Bio, LAVA Therapeutics (NASDAQ: LVTX), Sanifit Therapeutics (acquired by Vifor Pharma), Aura Biosciences (NASDAQ: AURA) and MedLumics.
He is also a member of the International Business Advisory Board of IRB Barcelona.